ReviewClinical and translational allergy2021
Omalizumab for successful chemotherapy desensitisation: What we know so far.
Review in Clinical and translational allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Combined omalizumab and desensitization to control IgE-mediated hypersensitivity in enzyme replacement therapy for late-onset Pompe disease.Orphanet journal of rare diseases · 2026Article
- Omalizumab as an Effective Therapy for Testosterone-induced Angioedema in a Transgender Person: A Case ReportEndocrine, metabolic & immune disorders drug targets · 2026Article
- Using Biologics in the Prevention of Anaphylaxis.Current allergy and asthma reports · 2025Review
- Recent Insights into the Epidemiology and Management of AnaphylaxisBalkan medical journal · 2025Review
- The Expanding Role of Omalizumab: From Food Allergy to Drug Desensitization.International journal of molecular sciences · 2025Review
- How to manage hypersensitivity reactions to enzyme replacement therapy in lysosomal storage diseases?Orphanet journal of rare diseases · 2025Review
- Perioperative anaphylaxis in children and first successful cisatracurium desensitization.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Article
- Successful Desensitization to Irinotecan in a Patient with Metastatic Esophageal Squamous Cell Carcinoma and a History of Anaphylaxis in Response to Irinotecan-Case Report and Literature Review.Journal of clinical medicine · 2024Article
- Progestogen Hypersensitivity.The journal of allergy and clinical immunology. In practice · 2023Article
- Immune Reactions in Major Types of Oncological Treatment.International journal of molecular sciences · 2023Review
- Therapeutical Targets in Allergic Inflammation.Biomedicines · 2022Review
- Omalizumab for successful chemotherapy desensitisation: What we know so far.Clinical and translational allergy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypersensitivity reactions induced by chemotherapeutic drugs may influence the course of the oncologic disease by preventing doctors from prescribing first-line therapy. In order to prevent another hypersensitivity reaction to the culprit chemotherapeutic agent, the physician can decide between two possibilities: premedication or desensitisation protocols. Rapid drug desensitisation showed successful results for most patients, but some of them may develop symptoms. Although omalizumab is not licensed as premedication or adjuvant therapy in chemotherapy desensitisation protocols, there have been published some case reports and small sample size studies that indicated promising results.
methodsWe reviewed all the published literature regarding the use of omalizumab during chemotherapy desensitisation protocols. RESULTS AND
conclusionsWe found a great heterogeneity between the doses and the interval between omalizumab injections and chemotherapy - rapid drug desensitisation, but most of the studies showed promising results. As a corollary, we propose a dose regimen of omalizumab administered before the first desensitisation protocol. Then, omalizumab should be administered one day before every chemotherapy regimen. Omalizumab might be used as an adjuvant therapy and might be a solution for a hopeless situation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.